Our study reveals that a pathological PTEN/Akt/FoxO3a/cav-1/Fas pathway protects IPF fibroblasts from polymerized collagen-induced apoptosis thereby facilitating their persistence in the collagen-rich matrix and suggests that a therapeutic approach targeting this altered pathway may limit IPF progression. The gene discussed is CAV1; the disease is idiopathic pulmonary fibrosis.